Whitehawk Therapeutics (WHWK) Cash & Equivalents (2010 - 2026)

Whitehawk Therapeutics (WHWK) has 17 years of Cash & Equivalents data on file, last reported at $34.8 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $34.8 million, down 84.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $34.8 million (down 84.71% YoY), and the FY2025 annual result was $37.6 million, up 31.04% from the prior year.
• Cash & Equivalents eased to $34.8 million in Q1 2026 per WHWK's latest filing, from $37.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $227.6 million in Q1 2025 and troughed at $28.7 million in Q4 2024.
• A 5-year average of $83.4 million and a median of $62.9 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents soared 432.47% in 2025, then slumped 84.71% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $39.0 million in 2022, then jumped by 61.17% to $62.9 million in 2023, then slumped by 54.41% to $28.7 million in 2024, then jumped by 31.04% to $37.6 million in 2025, then declined by 7.39% to $34.8 million in 2026.
• Business Quant data shows WHWK's Cash & Equivalents at $34.8 million in Q1 2026, $37.6 million in Q4 2025, and $162.6 million in Q3 2025.